Drugs / MR902
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02773316 | Sep → Nov 2015 | — | Mundipharma Research Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MR902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02773316 ↗ |
| Route | Oral | “MR902 50/0.5 mg PR tablets, single dose oral” NCT02773316 ↗ |